Group 1 - The company reported total revenue of approximately 13.273 billion RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 18.5% [1] - The reported profit attributable to shareholders was approximately 2.548 billion RMB, a decrease of 15.6% year-on-year, with basic earnings per share at 0.2229 RMB [1] - The decline in revenue was primarily due to the inclusion of the products Dumex® and Tsinghua® in centralized procurement [1] Group 2 - The gross profit margin decreased by 6.0 percentage points to 65.6%, mainly due to the reduced revenue share from prescription drugs [1] - Research and development expenses increased by 5.5% year-on-year to 2.683 billion RMB, accounting for 26.2% of prescription drug revenue [1] - The company has nearly 90 products in various stages of clinical trials, with 12 submitted for market approval and over 30 key products in the registration clinical stage [1] Group 3 - The company has over 200 innovative drugs and formulations in development, including more than 90 macromolecules, 60 small molecules, and 50 new formulations [1] - There are currently over 160 clinical trials ongoing, with nearly 60 in Phase III [1] - The company expects to submit over 50 new drugs or new indications for approval by the end of 2028 [1] Group 4 - Year-to-date, the company has received approval for 3 innovative products, acceptance for 5 product applications, breakthrough therapy designations for 4 products, and 28 clinical trial approvals [2] - The company also obtained 7 registration approvals for generic drugs and 9 clinical trial approvals for innovative drugs in North America, along with 1 fast track designation [2]
石药集团(01093.HK)中期股东应占溢利同比减少15.6%至25.48亿元 中期息14港仙